Over a billion people are affected by fungal infections every year, ranging in severity from topical skin conditions like athlete’s foot to life-threatening fungal blood infections.
The infection is more likely to occur when the body’s immune system is compromised due to an illness like HIV/AIDS, cancer or when receiving antibiotic treatment. There is a pressing need to develop efficient and disease-specific antifungal agents to mitigate this growing drug resistance problem. Traditional antifungal therapeutics need to get inside the cell to attack the infection but have trouble targeting and penetrating the fungi membrane wall. Also, since fungi are metabolically similar to mammalian cells, existing drugs can have trouble differentiating between healthy and infected cells. Recognizing this, IBM scientists applied an organic catalytic process to facilitate the transformation of PET (waste), into entirely new molecules that can be transformed into antifungal agents.
Researchers at Singapore’s Institute of Bioengineering and Nanotechnology (IBN) and California’s IBM Research -Almaden (IBM) have unveiled a nanomedicine breakthrough in common plastics like polyethylene terephthalate (PET) that can be converted into non-toxic and biocompatible materials designed to specifically target and attack fungal infections. This is significant as plastic bottles are typically recycled by mechanical grounding and can mostly be reused only in secondary products like clothes, carpeting or playground equipment.
These new antifungal agents self-assemble through a hydrogen-bonding process, sticking to each other like molecular Velcro in a polymer-like fashion to form nanofibers. This is important because these antifungal agents are only active as a therapeutic in the fiber or polymer-like form. This novel nanofiber carries a positive charge and can selectively target and attach to only the negatively-charged fungal membranes based on electrostatic interaction. It then breaks through and destroys the fungal cell membrane walls, preventing it from developing resistance.
According to Dr Yi Yan Yang, Group Leader, IBN, “The ability of these molecules to self-assemble into nanofibers is important because unlike discrete molecules, fibers increase the local concentration of cationic charges and compound mass. This facilitates the targeting of the fungal membrane and its subsequent lysis, enabling the fungi to be destroyed at low concentrations.” Leveraging IBM Research’s computational capabilities, the researchers simulated the antifungal assemblies, predicting which structural modifications would create the desired therapeutic efficacy. “As computational predictive methodologies continue to advance, we can begin to establish ground rules for self assembly to design complex therapeutics to fight infections as well as the effective encapsulation, transport and delivery of a wide variety of cargos to their targeted diseased sites,” said Dr. James Hedrick, Advanced Organic Materials Scientist, IBM Research. The minimum inhibitory concentration (MIC) of the nanofibers, which is the lowest concentration that inhibits the visible growth of fungi, demonstrated strong antifungal activity against multiple types of fungal infections. In further studies conducted by Singapore’s IBN, testing showed the nanofibers eradicated more than 99.9% of C. albicans, a fungal infection causing the third most common blood stream infection in the United States, after a single hour of incubation and indicated no resistance after 11 treatments. Conventional antifungal drugs were only able to suppress additional fungal growth while the infection exhibited drug resistance after six treatments.
Additional findings of this research indicated the nanofibers effectively dispersed fungal biofilms after one-time treatment while conventional antifungal drugs were not effective against biofilms. The in vivo antifungal activity of the nanofibers was also evaluated in a mouse model using a contact lens-associated C. albicans biofilm infection. The nanofibers significantly decreased the number of fungi, hindered new fungal structure growth in the cornea and reduced the severity of existing eye inflammation. These experiments also showed mammalian cells survived long after incubation with the nanofibers, indicating excellent in vitro biocompatibility. In addition, no significant tissue erosion is observed in the mouse cornea after topical application of the nanofibers.
In recent years, the number of opportunistic fungal infections has increased due to growing populations of patients with weakened immune systems, for example due to cancer, organ transplant or HIV/AIDS.
The Latest on: Antifungal agents
[google_news title=”” keyword=”Antifungal agents” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Antifungal agents
- Dermatology Drugs market is projected to grow at a CAGR of 6.2% by 2032: Visiongain Reports Ltdon November 21, 2022 at 8:32 am
Visiongain has published a new report entitled Dermatology Drugs 2022-2032. It includes profiles of Dermatology Drugs and Forecasts Market Segment by Disease (Psoriasis, Dermatitis, Acne, Skin ...
- 10 Best Antifungal Soapson November 18, 2022 at 4:00 pm
HERBOGANIC NEEM HERBAL SOAP is perfect to use on the face and entire body. Help prevent and clears up acne. It cleanses and moisturizes your skin, leaving you feeling and looking great! NEEM, a ...
- Management of Drug and Food Interactions with Azole Antifungal Agents in Transplant Recipientson November 18, 2022 at 4:00 pm
Azole antifungal agents are frequently used in hematopoietic stem cell and solid organ transplant recipients for prevention or treatment of invasive fungal infections. However, because of ...
- Antifungal Agents Market to Exhibit a Decent CAGR of 4.06% by 2032on November 18, 2022 at 2:46 am
Market.us has to return up with a brand new report specifically Global Antifungal Agents Market standing and Outlook (2022-2031) that focuses on current trade updates, providing exclusive and ...
- Management of Drug and Food Interactions with Azole Antifungal Agents in Transplant Recipientson November 17, 2022 at 4:00 pm
Elizabeth Dodds-Ashley, Pharm.D., M.H.S. Consequently, the influence of fluconazole inhibition must also be considered when removing this agent from the drug profile of a transplant recipient.
- Increase of Candida auris in the EU/EEA: Need for better surveillanceon November 17, 2022 at 1:27 pm
It is frequently resistant to the commonly used antifungal drugs, which leaves very limited treatment options. The European Centre for Disease Prevention and Control (ECDC) has been conducting surveys ...
- Anti-Microbial/Antifungal Tests Market Latest Developments and Innovations Across the Industryon November 16, 2022 at 9:32 am
Microbial and fungal infections are major causes of death worldwide and can even lead to epidemics, putting a significant economic burden on countries, particularly developing ones. Prevention is a ...
- Antifungal Drugs Market 2022 Share Booming Rapidly with Recent Trends, Development, Revenue, Demand and Forecast to 2027 | 102 Pages Reporton November 13, 2022 at 8:25 pm
Report Pages] Antifungal Drugs Market Analysis 2022 (Pre and Post Covid is covered and Report Customization is available) | by Product Type (Clotrimazole., Econazole., Miconazole., Terbinafine., ...
- Topical Antifungal Agents Market : Top Key Players, Industry Size, Share, Segmentation, Comprehensive Analysis and Forecast by 2028on November 3, 2022 at 7:57 pm
Nov 03, 2022 (The Expresswire) -- "Topical Antifungal Agents Market" research provides significant and in-depth information on the global market. This research provides an in-depth analysis and ...
- First WHO 'watch list' of health-threatening fungi releasedon October 25, 2022 at 9:49 am
At the top of the list are fungal species threatening health care that are already or have increasing resistance to antifungal agents, such as Aspergillus fumigatus and Candida Auris. During the ...
via Bing News